Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Martin P. Carroll, MD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, MDPhD, Sung June Lee, BA, Anil Kumar, PhD, Anne Lehman, Joseph Patrick Loftus, BS, Grace Jeschke, PhD, John D. Crispino, PhD, Thierry Besson, PhD, Junwei Shi, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141258

Published: 2020

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Neil Palmisiano, MD, Grace Jeschke, PhD, Lindsay Wilde, MD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 4267.

https://doi.org/10.1182/blood.V130.Suppl_1.4267.4267

Published: 2017

Journal Articles

Differentiation Response to Quizartinib, a Potent 2 nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy

Miguel Torres Martin, PhD, Grace Jeschke, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Maria E. Figueroa, MD

Blood (2017) 130 (Supplement 1): 3922.

https://doi.org/10.1182/blood.V130.Suppl_1.3922.3922

Published: 2017

Journal Articles

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Neil Palmisiano, MD, Grace Jeschke, PhD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 3858.

https://doi.org/10.1182/blood.V130.Suppl_1.3858.3858

Published: 2017

NARROW

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Differentiation Response to Quizartinib, a Potent 2 nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Differentiation Response to Quizartinib, a Potent 2 nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only